18.49
1.58 (9.34%)
| Previous Close | 16.91 |
| Open | 16.92 |
| Volume | 1,860,359 |
| Avg. Volume (3M) | 3,093,068 |
| Market Cap | 839,560,640 |
| Price / Sales | 18.04 |
| Price / Book | 7.80 |
| 52 Weeks Range | |
| Earnings Date | 13 Nov 2024 |
| Profit Margin | -146.86% |
| Operating Margin (TTM) | -575.24% |
| Diluted EPS (TTM) | -1.02 |
| Quarterly Revenue Growth (YOY) | -63.40% |
| Total Debt/Equity (MRQ) | 15.97% |
| Current Ratio (MRQ) | 1.37 |
| Operating Cash Flow (TTM) | -33.95 M |
| Levered Free Cash Flow (TTM) | -23.55 M |
| Return on Assets (TTM) | -44.49% |
| Return on Equity (TTM) | -392.69% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Capricor Therapeutics, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.25 |
|
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 16.75% |
| % Held by Institutions | 18.53% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Superstring Capital Management Lp | 30 Sep 2024 | 337,347 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 77.00 (HC Wainwright & Co., 316.44%) | Buy |
| Median | 37.50 (102.81%) | |
| Low | 25.00 (Maxim Group, 35.21%) | Buy |
| Average | 41.67 (125.37%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 16.10 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Jones Trading | 18 Nov 2024 | 40.00 (116.33%) | Buy | 18.38 |
| Cantor Fitzgerald | 14 Nov 2024 | 30.00 (62.25%) | Buy | 18.49 |
| HC Wainwright & Co. | 14 Nov 2024 | 77.00 (316.44%) | Buy | 18.49 |
| 11 Oct 2024 | 77.00 (316.44%) | Buy | 17.77 | |
| Piper Sandler | 21 Oct 2024 | 35.00 (89.29%) | Buy | 20.57 |
| Maxim Group | 25 Sep 2024 | 25.00 (35.21%) | Buy | 10.34 |
| Oppenheimer | 25 Sep 2024 | 43.00 (132.56%) | Buy | 10.34 |
| 23 Sep 2024 | 15.00 (-18.88%) | Buy | 5.97 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |